Literature DB >> 19180103

Systemic lupus erythematosus.

James Wentworth, Clare Davies.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19180103     DOI： 10.1038/nrd2743

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

Authors:  Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone
Journal:  Arthritis Rheum       Date:  2008-01
  1 in total
  2 in total

1.  Trial watch: BLYS-targeted antibody shows promise in Phase III SLE trial.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

2.  Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZB×NZW F1 mice via interference with TLR-mediated APC response.

Authors:  Shi-jun He; Ze-min Lin; Yan-wei Wu; Bing-xin Bai; Xiao-qian Yang; Pei-lan He; Feng-hua Zhu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2013-12-30       Impact factor: 6.150
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.